Influence of preparation Resalut® on lipid peroxidation, antioxidant status, a marker of cytolysis and cholestasis in patients with nonalcoholic fatty liver disease
- Authors: Myazin R.G1
-
Affiliations:
- Volgograd State Medical University of the Ministry of Health of the Russian Federation
- Issue: Vol 19, No 8-2 (2017)
- Pages: 55-58
- Section: Articles
- URL: https://ogarev-online.ru/2075-1753/article/view/94640
- DOI: https://doi.org/10.26442/2075-1753_19.8.2.55-58
- ID: 94640
Cite item
Full Text
Abstract
Purpose: evaluate the influence of preparation Resalut® on the dynamics of lipid peroxidation, antioxidant status, cytolysis syndrome, cholestasis, cholesterol level in patients with nonalcoholic fatty liver disease (NAFLD). Materials and methods: 70 patients with NAFLD were treated with preparation Resalut® and comparing the drug from a group of essential phospholipids. Levels of lipid peroxidation, antioxidant status, markers of cytolysis and cholestasis were determined before and after therapy course. Results: after the therapy in group of patients, threated by Resalut®, revealed a valuable positive dynamics of all indexes, improvement of the general status of patients after therapy. Conclusion: therapy with preparation Resalut® is an effective method of treatment nonalcoholic fatty liver disease.
Full Text
##article.viewOnOriginalSite##About the authors
R. G Myazin
Volgograd State Medical University of the Ministry of Health of the Russian Federation
Email: naclo@mail.ru
канд. мед. наук, каф. пропедевтики внутренних болезней, врач-гастроэнтеролог, врач-терапевт высшей квалификационной категории, член Российского общества по изучению печени. 400131, Russian Federation, Volgograd, pl. Pavshikh bortsov, d. 1
References
- Мехтиев С.Н., Гриневич В.Б., Кравчук Ю.А., Бращенкова А.В. Неалкогольная жировая болезнь печени: клиника, диагностика и лечение. Лечащий врач. 2008; 2: 24-8.
- Павлов Ч.С., Глушенков Д.В., Буличенко М.А. и др. Неалкогольная жировая болезнь печени в клинике внутренних болезней. Рус. мед. журн. 2011; 6: 11-7.
- Полунина Т.Е. Неалкогольная жировая болезнь печени. Алгоритм диагностики и лечебной тактики. Пособие для врачей общей практики, терапевтов и гастроэнтерологов. Учебно-методическое пособие. М.: Медиа Медика, 2014.
- Мязин Р.Г. Неалкогольная жировая болезнь печени: новые возможности терапии. Мед. совет. 2014; 13: 18-20.
- Диагностика и лечение неалкогольной жировой болезни печени. Методические рекомендации для врачей. Под ред. В.Т.Ивашкина. М.: РОПИП, 2015.
- Sass D.A, Parke Change, Kapil B. Chopra. Nonalcoholic Fatty Liver Disease: A Clinical Review. Digest Dis Sci 2005; 50 (1): 171-80.
- Garc M.C. Non-alcoholic steatohepatitis. J Gastroenterol Hepatol 2001; 24: 395-402.
- Donnelly K.L, Smith C.I, Schwarzenberg S.J et al. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with non-alcoholic fatty liver disease. J Clin Invest 2005; 115 (5): 1343-51.
- Gonciarz Z. et al. Randomised placebo-controlled double-blind trial on essential phospholipids in the treatment of fatty liver associated with diabetes. Med Chir Digest 1988; 17 (1): 61-5.
- Yin Kong. Observation for curative effect of Essentiale in treatment of fatty liver caused by diabetes mellitus. Med J Q 2000; 15: 277-8.
- Sun C. et al. Clinical Observation on Polyene Phosphatidyl Choline and Metformin in the Treatment of Type 2 Diabetes and Non-alcoholic Fatty Liver Disease. Clin Focus 2008; 23 (17): 1272-3.
- Sas E., Grinevich V., Efimov O, Sherbina N. et al. Beneficial influence of polyunsaturated Phosphatidylcholine enhances functional liver condition and liver structure in patients with Nonalcoholic steatohepatitis. Results of prolonged randomized blinded prospective clinical study. J Hepatol 2013; 58: 549.
- Dajani A. et al. EPL in the management of primary NAFLD and NAFLD associated with comorbid disease. Hepatol Int 2013; 7 (Suppl. 1): 108.
Supplementary files
